Table 1

Disease characteristics at baseline of the 1301 included patients

Patients with SScPatients with synovitis (n=234)Patients with TFRs (n=166)
Age (years), mean±SD55±1554±1356±14
Women/men, n (%)1079 (83)/222 (17)192 (82)/42 (18)119 (72)/47 (28)
Cutaneous subset*, n (%)
Limited801/1301 (62)108/234 (46)48/166 (29)
Diffuse500/1301 (38)126/234 (54)118/166 (71)
Joint synovitis, n (%)234/1301 (18)NA62/166 (37)
TFRs, n (%)166/1301 (13)62/234 (26)NA
mRSS >14, n (%)382/1285 (30)87/226 (36)104/165 (63)
History of digital ulcers, n (%)364/1296 (28)74/234 (32)52/166 (31)
Pulmonary fibrosis on CT-scan, n (%)361/1276 (28)88/227 (39)70/161 (43)
FVC <75% predicted, n (%)305/1286 (24)59/231 (26)52/161 (33)
DLCO <75% predicted, n (%)490/1216 (40)88/232 (38)73/166 (44)
Positive antinuclear antibodies (>1/160), n (%)1208/1301 (93)222/234 (95)156/166 (94)
Positive for antitopoisomerase-1 antibodies, n (%)457/1301 (35)120/234 (51)90/166 (54)
Positive for anticentromere antibodies, n (%)377/1301 (29)42/234 (18)14/166 (8)
Elevated acute phase reactants, n (%)311/1301 (24)55/234 (24)42/166 (25)
Treatment with corticosteroids at baseline, n (%)351/1301 (27)97/234 (41)75/166 (45)
Treatment with methotrexate at baseline, n (%)143/1301 (11)64/234 (27)50/166 (30)
Treatment with immunosuppressive drugs at baseline, n (%)364/1301 (28)86/234 (37)81/166 (49)
  • *The cutaneous subset classification was determined according to the LeRoy criteria and based on physician's own decision according to the knowledge and training during the EUSTAR courses. Diffuse and limited cutaneous SSc could not be considered mutually exclusive.

  • DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; mRSS, modified Rodnan Skin Score; NA, not applicable; SSc, systemic sclerosis; TFRs, tendon friction rubs.